KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.
B cells
KRAS
LUAD
immunotherapy
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Aug 2019
09 Aug 2019
Historique:
received:
02
07
2019
revised:
01
08
2019
accepted:
06
08
2019
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
14
8
2019
Statut:
epublish
Résumé
Non-small-cell lung cancer, histologically classified into adenocarcinoma (AD) and squamous cell carcinoma, is one of the most deadly malignancies worldwide. Lung AD (LUAD) could benefit of a plethora of target therapies and, in the last few years, also of immunotherapies. Here we focused on a real-life cohort of LUAD and The Cancer Genome Atlas (TCGA)-LUAD dataset aiming to gain insights into the immune contexture of such a malignancy. We explored the mutational status of 41 genes and the expression of 94 genes, related to immune-checkpoint, inflammation, and stromal microenvironment. Surprisingly, we found that our cohort has a very low mutational burden if we consider our panel as its surrogate. Regarding gene expression data, we identified 31 genes significantly deregulated in tumor tissues compared with a pool of normal samples. Unsupervised hierarchical clustering of the deregulated genes is able to identify two clusters of tumor samples, differently enriched in alterations in actionable genes. In particular, we identified a cluster enriched in patients carrying
Identifiants
pubmed: 31405063
pii: cancers11081145
doi: 10.3390/cancers11081145
pmc: PMC6721568
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5
pubmed: 10781081
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Cancer Immunol Immunother. 2004 Jul;53(7):589-99
pubmed: 14745515
Cancer Cell. 2004 Nov;6(5):447-58
pubmed: 15542429
Br J Cancer. 2005 Jan 17;92(1):131-9
pubmed: 15597105
PLoS One. 2010 Jun 04;5(6):e10966
pubmed: 20532039
Nat Rev Drug Discov. 2011 Aug 01;10(8):591-600
pubmed: 21804596
J Natl Cancer Inst. 2012 Feb 8;104(3):228-39
pubmed: 22247021
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Cancer Lett. 2013 Jun 10;333(2):222-8
pubmed: 23370224
Sci Transl Med. 2013 Oct 30;5(209):209ra153
pubmed: 24174329
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Nat Med. 2014 Apr;20(4):342-4
pubmed: 24710377
Cancer Cell. 2014 May 12;25(5):621-37
pubmed: 24823639
J Thorac Oncol. 2014 Oct;9(10):1513-22
pubmed: 25170638
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Natl Cancer Inst. 2015 Feb 03;107(3):null
pubmed: 25650315
Respirology. 2015 Apr;20(3):370-8
pubmed: 25689095
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Oncoimmunology. 2015 Jan 30;4(1):e955704
pubmed: 25949859
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186
Nat Protoc. 2015 Oct;10(10):1556-66
pubmed: 26379229
Oncotarget. 2015 Oct 20;6(32):34014-22
pubmed: 26416458
J Immunol. 2016 Feb 15;196(4):1678-85
pubmed: 26773157
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Ann Oncol. 2016 Nov;27(11):2117-2123
pubmed: 27502728
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Biomark Res. 2017 Mar 15;5:12
pubmed: 28331612
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Cancer Immunol Immunother. 2017 Sep;66(9):1175-1187
pubmed: 28451792
Nat Rev Cancer. 2017 Aug 24;17(9):569
pubmed: 28835723
Cancer Immunol Res. 2017 Oct;5(10):898-907
pubmed: 28848053
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Expert Opin Ther Targets. 2018 May;22(5):453-461
pubmed: 29561217
J Thorac Dis. 2018 Mar;10(3):1248-1252
pubmed: 29708132
Cancers (Basel). 2018 Jul 27;10(8):null
pubmed: 30060457
EBioMedicine. 2018 Oct;36:196-208
pubmed: 30268834
Front Oncol. 2018 Sep 19;8:384
pubmed: 30283732
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279
pubmed: 30393621
Nat Rev Cancer. 2019 Jan;19(1):9-31
pubmed: 30532012
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
pubmed: 9050879
J Exp Med. 1998 Jan 19;187(2):265-70
pubmed: 9432985